Screener

Research and development collaborations (note 11)

Zymeworks·Products & Services·14 segments·Rolls up to Total Revenue

Breakdown

Segment	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26	Q2 '26
Other drug supply	$6.03M	$2.11M	$2.15M	$7K	$71K	$0	$117K	$1.66M
Royalties	$0	$100K	$202K	$550K	$831K	$898K	$1.33M	$1.59M
Drug supply for ongoing studies	$5.27M	$3.76M	$2.96M	$1.84M	$970K	$780K	$345K	$791K
Development support payments	$764K	—	$4.49M	$475K	$352K	$296K	$392K	$291K
Milestone revenue	$2.5M	$25M	$14M	$20M	$25M	—	$0	$0
Option exercise fee	$0	$15M	—	$7.5M	$0	—	—	$0
Recognition of deferred revenue	—	—	—	—	—	—	—	$0
Total	$16M	$31.03M	$27.11M	$48.73M	$27.61M	$2.52M	$2.41M	$4.59M

Bispecific Antibodies, Commercial and Development Milestones, Commercial Sales Milestones, Metastatic Castration-Resistant Prostate Cancer, Research, Development and Commercial Milestones, Research Milestone, Technology Access Fee are derived from annual filings.

Segments

Bispecific AntibodiesView metric

Commercial and Development MilestonesView metric

Commercial Sales MilestonesView metric

Development support paymentsView metric

Drug supply for ongoing studiesView metric

Metastatic Castration-Resistant Prostate CancerView metric

Milestone revenueView metric

Option exercise feeView metric

Other drug supplyView metric

Recognition of deferred revenueView metric

Research, Development and Commercial MilestonesView metric

Research MilestoneView metric

RoyaltiesView metric

Technology Access FeeView metric